Nonetheless, the PI3K/Akt/rapamycin-sensitive mTOR complex pathways remain important as targets for new GBM drugs since activation of PI3CA (p110) or PIK3R1 (P85), or loss of PTEN expression has been estimated to be around 88% (Li et al., 2016). Here, PIK3R1 is linked to glioblastoma.